Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has cleared its investigational new drug application to begin clinical development of its pipeline candidate, VX-407, for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Vertex plans to begin a phase I study on VX-407 in ADPKD later this month.VX-407 is a first-in-class small molecule corrector that targets the underlying cause of this common inherited kidney disease, which leads to growth of several kidney-enlarging cy ...

Solskin/DigitalVision via Getty Images Vertex Pharmaceuticals (NASDAQ:VRTX) is a promising biotechnology with solid financial results in 2023, a dominant Cystic fibrosis ("CF") franchise, and is on track to diversify its drug portfolio by launching five new products by 2028, which include its newest CF drug, a non-opioid pain management drug, and a therapy addressing Sickle Cell Disease and Beta-Thalassemia. Several of these solutions have the potential to produce blockbuster status. Investors were excited ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $411.38, reflecting a +0.91% shift from the previouse trading day's closing. The stock's change was more than the S&P 500's daily gain of 0.63%. At the same time, the Dow added 0.2%, and the tech-heavy Nasdaq gained 0.82%.Prior to today's trading, shares of the drugmaker had lost 3.44% over the past month. This has lagged the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76% in that time.The investment communit ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Leerink Partners Global Biopharma Conference Call March 11, 2024 4:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants David Risinger - Leerink Partners David Risinger Good afternoon, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners [ph]. Two members of the Vertex leadership team; immediately to ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Leerink Partners Global Biopharma Conference Call March 11, 2024 4:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants David Risinger - Leerink Partners David Risinger Good afternoon, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners [ph]. Two members of the Vertex leadership team; immediately to ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 10:30 AM ET Company Participants David Altshuler - Executive Vice President, Research and Chief Scientific Officer Charlie Wagner - Executive Vice President and Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen’s 44th Annual Healthcare Conference. I am Phil Nadeau, one of the biotech analysts, and it’s my pleas ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 10:30 AM ET Company Participants David Altshuler - Executive Vice President, Research and Chief Scientific Officer Charlie Wagner - Executive Vice President and Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen’s 44th Annual Healthcare Conference. I am Phil Nadeau, one of the biotech analysts, and it’s my pleas ...

My first response when thinking about the ultimate growth stock to buy with $1,000 right now was to go with a high-flying AI stock. But the more I deliberated, the less comfortable I was choosing one of those stocks.Don't get me wrong. I like (and own) several great AI stocks. However, I could easily name downsides to all of them. So which stock do I think is the ultimate pick to buy with $1,000 right now? After careful consideration, my answer is... Vertex Pharmaceuticals (VRTX 0.78%).Accentuating the posi ...

Vertex Pharmaceuticals (VRTX -0.96%) has wowed investors in recent times as it's expanded beyond its specialty area of cystic fibrosis (CF) treatment. The company launched Casgevy, a one-time curative gene editing treatment for blood disorders sickle cell disease and beta thalassemia. And Vertex recently reported positive data from trials of its pain management candidate and aims to file for regulatory review this year.All of this is great and could result in billions of dollars in revenue. But Vertex also ...

Vertex Pharmaceuticals (VRTX -0.96%) is the global leader in cystic fibrosis (CF) treatment, and that specialty has helped it generate billions of dollars in earnings. But the company has also spent the past few years developing candidates outside of this treatment area, in an effort to become a well-diversified biotech player.In fact, Vertex's next product to market may be one that could treat one of the most common problems around -- pain -- and generate blockbuster revenue. The company aims to submit tha ...